Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa Bowerman

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Gene Therapy|April 22, 2020
Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy miceNina Ahlskog, Daniel Hayler, Anja Krueger, et al.
Turkish Journal of Biology = Turk Biyoloji Dergisi|April 30, 2026
Modulating microtubule stability via α-tubulin acetylation partially restores Golgi fragmentation in spinal muscular atrophyPelin Zobaroğlu Özer, Memet Gözüböyük, Özge Çetin, et al.
Annals of Neurology|August 29, 2012
Glucose metabolism and pancreatic defects in spinal muscular atrophyMelissa Bowerman, Kathryn J Swoboda, John-Paul Michalski, et al.
Molecular Therapy. Nucleic Acids|February 12, 2021
Targeting the 5' untranslated region of <i>SMN2</i> as a therapeutic strategy for spinal muscular atrophyAudrey M Winkelsas, Christopher Grunseich, George G Harmison, et al.
Human Molecular Genetics|July 27, 2023
AAV9-mediated SMN gene therapy rescues cardiac desmin but not lamin A/C and elastin dysregulation in Smn2B/- spinal muscular atrophy miceSharon J Brown, Darija Šoltić, Silvia A Synowsky, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 14, 2016
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophySuzan M Hammond, Gareth Hazell, Fazel Shabanpoor, et al.
JCI Insight|July 8, 2021
Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophyKatharina E Meijboom, Viola Volpato, Jimena Monzón-Sandoval, et al.
Human Molecular Genetics|July 9, 2018
Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy miceLisa M Walter, Christiane E Koch, Corinne A Betts, et al.
Cells|November 6, 2020
A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMNSebastian Rademacher, Nora T Detering, Tobias Schüning, et al.
Neurobiology of Disease|June 26, 2017
KCC3 loss-of-function contributes to Andermann syndrome by inducing activity-dependent neuromuscular junction defectsMelissa Bowerman, Céline Salsac, Véronique Bernard, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Gene Therapy|April 22, 2020
Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy miceNina Ahlskog, Daniel Hayler, Anja Krueger, et al.
Turkish Journal of Biology = Turk Biyoloji Dergisi|April 30, 2026
Modulating microtubule stability via α-tubulin acetylation partially restores Golgi fragmentation in spinal muscular atrophyPelin Zobaroğlu Özer, Memet Gözüböyük, Özge Çetin, et al.
Annals of Neurology|August 29, 2012
Glucose metabolism and pancreatic defects in spinal muscular atrophyMelissa Bowerman, Kathryn J Swoboda, John-Paul Michalski, et al.
Molecular Therapy. Nucleic Acids|February 12, 2021
Targeting the 5' untranslated region of <i>SMN2</i> as a therapeutic strategy for spinal muscular atrophyAudrey M Winkelsas, Christopher Grunseich, George G Harmison, et al.
Human Molecular Genetics|July 27, 2023
AAV9-mediated SMN gene therapy rescues cardiac desmin but not lamin A/C and elastin dysregulation in Smn2B/- spinal muscular atrophy miceSharon J Brown, Darija Šoltić, Silvia A Synowsky, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 14, 2016
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophySuzan M Hammond, Gareth Hazell, Fazel Shabanpoor, et al.
JCI Insight|July 8, 2021
Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophyKatharina E Meijboom, Viola Volpato, Jimena Monzón-Sandoval, et al.
Human Molecular Genetics|July 9, 2018
Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy miceLisa M Walter, Christiane E Koch, Corinne A Betts, et al.
Cells|November 6, 2020
A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMNSebastian Rademacher, Nora T Detering, Tobias Schüning, et al.
Neurobiology of Disease|June 26, 2017
KCC3 loss-of-function contributes to Andermann syndrome by inducing activity-dependent neuromuscular junction defectsMelissa Bowerman, Céline Salsac, Véronique Bernard, et al.
Pageof 4